DRICLOR Cutaneous Powder 0.20 %w/w
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
20-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ALDIOXA
Available from:
Stiefel Laboratories (U.K.) Ltd.
Dosage:
0.20 %w/w
Pharmaceutical form:
Cutaneous Powder
Authorization date:
1984-10-01
Summary of Product characteristics
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Driclor Powder
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Aldioxa 0.20 % w/w.
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Cutaneous powder
An off-white, absorbent, light free flowing cutaneous powder with a slight odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Driclor Powder is indicated in the management of intertrigo, hyperhidrosis and bromidrosis and in the prevention of
Tinea pedis and related conditions.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The affected area should be dried as thoroughly as possible before applying Driclor Powder. Driclor Powder should be
smoothed over the surface of the skin, between joints and folds.
4.3 CONTRAINDICATIONS
Known hypersensitivity to the ingredients.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
As with all powders, care should be taken to avoid inhalation.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
None.
4.6 PREGNANCY AND LACTATION
There are no restrictions on the use of Driclor Powder in pregnancy and lactation.
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
None.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 07/12/2006_
_CRN 2030889_
_page number: 1_
4.8 UNDESIRABLE EFFECTS
None.
4.9 OVERDOSE
Not applicable.
5 PHARMACOLOGICAL PROPERTIES
5.1 PHARMACODYNAMIC PROPERTIES
Driclor Powder contains aluminium dihydroxyallantoinate. Aluminium exerts a bacteriostatic action while allantoin
promotes phagocytosis.
Allantoin also acts as a hydrogen bond breaker, reducing hyperkeratinisation by its action on the intercellular cement.
The leucocytic stimulant effects of allantoin cause debridement of necrotic tissue and generation of new tissue.
The anti-irrit
Read the complete document
